Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02825797 · ClinicalTrials.gov registry record · Phase 1
3BNC117 and 10-1074 in HIV-infected Individuals
A Phase 1 study, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT02825797 is a Phase 1 study that has completed, run by Rockefeller University. The registered enrollment target is 34 participants.
The verdict
NCT02825797, a Phase 1 study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is a phase 1b clinical trial to evaluate the safety, pharmacokinetics and the antiretroviral effects of the combination of two anti-human immunodeficiency virus (HIV) broadly neutralizing antibodies, 3BNC117 and 10-1074, administered intravenously in HIV-infected individuals. This study is intended to support the development of the combination of 3BNC117 and 10-1074 mAbs for use in the treatment of HIV-1 infection.
Interventions
- DRUG Placebo
- DRUG 3BNC117
- DRUG 10-1074
- OTHER Analytical treatment interruption
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-06 |
| Est. Completion | 2018-08-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02825797
The ClinicalTrials.gov registry entry for NCT02825797 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02825797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02825797 about?
NCT02825797 is a clinical study titled "3BNC117 and 10-1074 in HIV-infected Individuals". This is a phase 1b clinical trial to evaluate the safety, pharmacokinetics and the antiretroviral effects of the combination of two anti-human immunodeficiency virus (HIV) broadly neutralizing antibodies, 3BNC117 and 10-1074, administered intravenously in HIV-infected individuals. This study is inte...
What is the current status of trial NCT02825797?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2016-06. Estimated completion is 2018-08-15.
What interventions are being tested in trial NCT02825797?
The interventions under investigation include: Placebo (DRUG), 3BNC117 (DRUG), 10-1074 (DRUG), Analytical treatment interruption (OTHER).
Who is sponsoring clinical trial NCT02825797?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.